GSK Annual Report 2008 203 Shareholder information Shareholder information The Ordinary Shares of the company are listed on the London Dividends per ADS Stock Exchange and on the New York Stock Exchange NYSE The table below sets out the dividends per ADS in US dollars in in the form of American Depositary Shares ADS.
For details of the last five years, translated into US dollars at applicable listed debt and where it is listed refer to Note 32, Net debt.
The companys share price increased by 0.5% in 2008.
This compares Q4 2008 11th February 2009 13th February 2009 9th April 2009 with a decrease in the FTSE 100 index of 31% during the year.
Q2 2009 29th July 2009 31st July 2009 8th October 2009 Q3 2009 4th November 2009 6th November 2009 7th January 2010 Market capitalisation The market capitalisation, based on shares in issue excluding Treasury shares, of GlaxoSmithKline at 31st December 2008 was Financial reporting calendar 67 billion.
At that date GSK was the fifth largest company by Publication Date market capitalisation on the FTSE index.
Results announcements SmithKline Beecham plc Floating Rate Unsecured Quarter 1 April 2009 Quarter 2 July 2009 Loan Stock 1990 2010 Quarter 3 October 2009 The loan stock is not listed on any exchange but holders may require Preliminary Quarter 4 January 2010 SmithKline Beecham plc to redeem their loan stock at par, i. e. 1 for every 1 of loan stock held, on the first business day of March, June, Annual report summary February March 2010 September and December.
Holders wishing to redeem all or part Results announcements of their loan stock should complete the notice on the back of their Results announcements are issued to the London Stock Exchange loan stock certificate and return it to the registrar, to arrive at least and are available on its news service.
Shortly afterwards, they are 30 days before the relevant redemption date.
issued to the media, are made available on the website and sent to Taxation the US Securities and Exchange Commission and the NYSE.
General information concerning the UK and US tax effects of share Financial reports ownership is set out on page 206 Taxation information for shareholders.
GSK publishes an Annual Report and for the shareholder not needing the full detail of the Report, a Summary document.
These are Dividends available from the date of publication on the website.
The Summary GlaxoSmithKline pays dividends quarterly.
It continues to increase is sent to all shareholders.
Shareholders may elect to receive the cash returns to shareholders through its dividend policy.
Dividends Annual Report by writing to the registrars.
Alternatively shareholders remain an essential component of total shareholder return and may elect to receive notification by email of the publication of GSK is committed to increasing its dividend over the long-term.
financial reports by registering on www.
Details of the dividends declared, the amount and the payment dates are given in Note 16 to the financial statements, Dividends.
Copies of previous financial reports are available on GSKs website.
Printed copies can be obtained from the registrars in the UK and Dividends per share from the GSK Response Center in the USA.
The table below sets out the dividends per share in the last five years.
Corporate responsibility report Year pence In late March 2009, GSK will publish on the website its 2008 57 Corporate Responsibility Report covering performance in areas 2007 53 including community investment, ethics and integrity, access to 2006 48 medicines, R&D and environment, health and safety.
2005 44 2004 42 204 GSK Annual Report 2008 Shareholder information Shareholder information continued Nature of trading market Annual General Meeting 2009 The following tables set out, for the periods indicated, the high The Queen Elizabeth II Conference Centre, 20th May 2009 and low middle market closing quotations in pence for the shares Broad Sanctuary, Westminster, on the London Stock Exchange, and the high and low last reported London SW1P 3EE sales prices in US dollars for the ADS on the NYSE.
The AGM is the companys principal forum for communication Pence per share with private shareholders.
In addition to the formal business High Low there will be a presentation by the Chief Executive Officer on the Quarter ended 31st March 2009 1305 1106 performance of the Group and its future development.
There will February 2009 1277 1106 be opportunity for questions to the Board, and the Chairmen of January 2009 1305 1215 the Boards Committees will take questions on matters relating to December 2008 1285 1102 those committees.
November 2008 1250 1066 October 2008 1229 995 Investors holding shares through a nominee service should September 2008 1327 1185 arrange with that nominee service to be appointed as a corporate Quarter ended 31st December 2008 1285 995 representative or proxy in respect of their shareholding in order to Quarter ended 30th September 2008 1327 1103 attend and vote at the meeting.
Quarter ended 30th June 2008 1153 1053 ADR holders wishing to attend the meeting must obtain a proxy Quarter ended 31st March 2008 1385 1001 Quarter ended 31st December 2007 1333 1160 from The Bank of New York Mellon which will enable them to Quarter ended 30th September 2007 1341 1215 attend and vote on the business to be transacted.
ADR holders Quarter ended 30th June 2007 1488 1272 may instruct The Bank of New York Mellon as to the way in Quarter ended 31st March 2007 1493 1344 which the shares represented by their ADR should be voted by Year ended 31st December 2006 1577 1326 completing and returning the voting card provided by the bank in Year ended 31st December 2005 1544 1175 accordance with the instructions given.
Year ended 31st December 2004 1299 1042 Documents on display The Memorandum and Articles of Association of the company US dollars per ADS and other documents referred to in this Annual Report are High Low available for inspection at the Registered Office of the company.
Quarter ended 31st March 2009 39.24 31.91 February 2009 37.36 31.91 Exchange controls and other limitations January 2009 39.24 34.09 affecting security holders December 2008 37.88 32.02 There are currently no UK laws, decrees or regulations November 2008 40.19 32.54 restricting the import or export of capital or affecting the October 2008 43.39 35.41 remittance of dividends or other payments to holders of the September 2008 47.01 42.08 companys shares who are non-residents of the UK.
There are Quarter ended 31st December 2008 43.39 32.02 no limitations relating only to non-residents of the UK under Quarter ended 30th September 2008 49.03 42.08 English law or the companys Memorandum and Articles of Quarter ended 30th June 2008 45.36 41.39 Association on the right to be a holder of, and to vote in Quarter ended 31st March 2008 54.36 40.85 respect of, the companys shares.
Quarter ended 31st December 2007 54.14 47.87 Quarter ended 30th September 2007 54.23 49.43 Quarter ended 30th June 2007 59.35 51.28 Quarter ended 31st March 2007 58.37 52.66 Year ended 31st December 2006 58.38 50.15 Year ended 31st December 2005 53.53 44.48 Year ended 31st December 2004 47.50 39.04 to 24th February 2009 Internet Information about the company including details of the share price is available on GSKs website at www.
Information made available on the website does not constitute part of this Annual Report.
GSK Annual Report 2008 205 Shareholder information Shareholder information continued Duplicate publications ADR programme administrator Queries relating to receipt of duplicate copies of GSKs The ADR programme is administered by: BNY Mellon Shareowner Services publications should be addressed to the registrars.
PO Box 358516 Investor relations Pittsburgh, PA 15252-8516 Investor Relations may be contacted as follows: www.
com shareowner Tel: 1 877 353 1154 US toll free UK Tel: 1 201 680 6825 outside USA 980 Great West Road, Brentford, Middlesex TW8 9GS email: shrrelations@bnymellon.
com Tel: 44 0 20 8047 5000 The administrators also provide Global BuyDIRECT, a direct ADS USA purchase sale and dividend reinvestment plan for ADR holders.
One Franklin Plaza, PO Box 7929, Philadelphia PA 19101 Tel: 1 888 825 5249 US toll free GSK Response Center Tel: 1 215 751 4000 outside USA Tel: 1 888 825 5249 US toll free Registrar The provision of the details above is not intended to be an The companys registrars are: invitation or inducement to engage in an investment activity.
Equiniti Advice on share dealing should be obtained from a stockbroker or Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA independent financial adviser.
co. uk Tel: 0871 384 2991 inside the UK Tel: 44 0 121 415 7067 outside the UK Equiniti also provides the following services: Nominee dealing account and Individual Savings Account ISA GlaxoSmithKline Corporate Sponsored Nominee Shareview service Share dealing service Dividend Reinvestment Plan Share dealing service Shareholders may trade shares, either held in certificates or in the Corporate Sponsored Nominee by internet or telephone through Shareview dealing, a share dealing service provided by Equiniti.
For internet deals log on to www.
For telephone deals call 08456 037 037 inside the UK only.
For the nominee and ISA service, either www.
Telephone services are available between 8.00 and 18.00, Monday to Friday market trading hours 8.00 - 16.30.
Glaxo Wellcome and SmithKline Beecham Corporate PEPs The Share Centre Limited Oxford House, Oxford Road, Aylesbury, Bucks HP21 8SZ Tel: 44 0 1296 414141
